Unapproved fat-dissolving products sold online
This article was originally published in The Tan Sheet
Executive SummaryFDA sent warning letters to U.S. health spas and a Brazil-based online retailer, which operates the Web sites zipmed.net and mesoone.com, about unapproved "lipodissolve" products and procedures. Lipodissolve involves drug injections intended to dissolve and permanently remove pockets of fat. The most commonly injected substances are the lecithin phosphatidylcholine and the bile acid dioxycholate, usually together and combined with vitamins, minerals and herbal extracts. A third substance that is an approved drug to treat respiratory problems in premature infants, Forest's Infasurf (calfactant), also has been found in lipodissolve formulations, according to FDA. The agency has received reports of permanent scarring, hard lumps and dark spots on consumers' skin after lipodissolve treatments. While FDA sent a warning letter about lipodissolve to only one Web retailer, more sites likely sell the products directly to consumers, Kathleen Anderson, deputy director in the Center for Drug Evaluation and Research's Division of New Drugs and Labeling Compliance, said during an April 6 conference call
You may also be interested in...
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.